Vencepa 25 Ps, 50 Ps & 50 Prefill Pen 25 mg, 50 mg Parenteral
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
Dosage (summary)
Adults: 25 mg twice weekly or 50 mg weekly. Children: 0.4 mg/kg (max 25 mg) twice weekly or 0.8 mg/kg (max 50 mg) weekly.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if clearly needed; crosses placenta and may increase infection risk in infants. Excreted in breast milk.
Key Drug Interactions
- Anakinra
- Abatacept
- Sulfasalazine
Contraindications
- Hypersensitivity to etanercept
- Active infections
- Sepsis
Common side effects
- Injection site reactions
- Infections
- Headache
- Allergic reactions
Counselling Points
- Monitor for infections
- Avoid live vaccines
- Report signs of TB or infections
- Consider contraception during treatment
Serious warnings
- Serious infections
- Tuberculosis risk
- Malignancies
- Hepatitis B reactivation
Important Disclaimer
The Vencepa 25 Ps, 50 Ps & 50 Prefill Pen 25 mg, 50 mg Parenteral professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
